malignant neoplasm of the breast
Conditions
Interventions
There will be two treatment groups. The first group with 32 participants will be applied to TENS, model TENS-FESHTM, before the infusion of the chemotherapeutic drugs for 30 minutes. The self-adhesive
Other
E02.331.800
HP3.073.433.101
Sponsors
universidade federal de santa maria
universidade federal de santa maria
Eligibility
Sex/Gender
Female
Age
35 Years to 75 Years
Inclusion criteria
Inclusion criteria: Women with indications of chemotherapy neoadjuvant or adjuvant, of high and moderate emetogenic potential; age between 35 and 75 years
Exclusion criteria
Exclusion criteria: Central nervous system metastasis;second chemotherapy treatment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction of nausea and vomiting during chemotherapy verified through the Edmonton and MASCC Antiemesis Tool questionnaires, from a significant variation of 35% intensity and 36% in the frequency of nausea and 30% in the frequency of vomiting. | — |
Secondary
| Measure | Time frame |
|---|---|
| Preservation of the body mass during the chemotherapy verified by means of the measurement of scale, from the finding of an average variation of a maximum of 30%. ;Preservation of the quality of life during chemotherapy verified through the questionnaires European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC-C30) and European Organization for Research and Treatment of Cancer Quality of Life Supplementary Questionnaire Breast Cancer Module (EORTC QLQ - BR23), from the finding of an average variation of maximum 30%.;Reduction in the intake of antiemetic drugs during chemotherapy verified through the MASCC Antiemesis Tool questionnaire, based on a significant variation of 30% in the frequency of medication intake.;Reduction of fatigue during chemotherapy verified through the Functional Assessment of Cancer Therapy Fatigue (FACT-F) questionnaire, based on the observation of a significant variation of 30% of the fatigue.;Preservation of emotional state during chemotherapy was verified using the Beck Depression Inventory (BDI) and Beck Anxiety Inventory (BAI) questionnaire, based on a significant variation of 30% in depression and anxiety, respectively.;Preservation of functionality during chemotherapy verified using the questionnaire World Health Organization Disability Assessment Schedule (WHODAS), Functional Independence Measure (MIF), Karnofsky Index, Eastern Cooperative Oncologic Group (ECOG) Performance Scale, based on a significant 30% variation in functionality.;Preservation of sleep quality during chemotherapy verified through the Questionnaire Questionnaire Pittsburgh Sleep Quality Index (PSQI), based on the observation of a significant variation of 30% of the quality of life. | — |
Countries
Brazil
Contacts
Public Contacthedioneia pivetta
universidade federal de santa maria
Outcome results
None listed